Currentblue cross blue shield - tennesseePolicy N/A

Epithelial Cell Cytology in Breast Cancer Risk Assessment

Defines coverage position for cytologic analysis of epithelial cells obtained via nipple aspiration or ductal lavage (including suction techniques) to assess breast cancer risk or manage high-risk patients; describes clinical evidence, guideline positions, and regulatory context.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyEpithelial Cell Cytology in Breast Cancer Risk Assessment

Policy CodePolicy N/A

Change Typeclarified

Effective DateN/A

Next Review DateN/A

Key ActionVerify the individual's benefit coverage and applicable Medicare/Medicaid specifications when applying these coverage criteria.

SourceLink

POLICY UPDATE CHANGES

Policy states that cytologic analysis of epithelial cells from nipple aspirations/ductal lavage to assess breast cancer risk does not meet coverage criteria.

Not coveredPrimary Coverage Position

SeveralGuideline/Regulatory References

Coverage Summary

This policy covers cytologic analysis of epithelial cells obtained via nipple aspiration and ductal lavage (including suction techniques) for assessment of nipple discharge and breast cancer risk. The policy's scope is limited to use of these specimens for risk assessment or management of patients at high risk of breast cancer and reflects current guideline and regulatory positions. The coverage stance is: Does not meet coverage criteria, consistent with statements from guideline and regulatory bodies (NCCN, ACR, FDA) that do not support routine use of ductal lavage or nipple aspirate cytology as screening or diagnostic substitutes for established breast cancer detection methods.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not Covered / Experimental

Rationale for non-coverage: evidence demonstrates low sensitivity and variable specificity of nipple discharge cytology — a large retrospective study reported sensitivity 17% and specificity 66% (Kooistra et al., 2009).

Prospective data are limited: a systematic review/meta-analysis found abnormal cytology in nipple aspirate fluid was associated with an approximately 2.1-fold higher risk of future breast cancer in the two prospective studies included, but overall evidence is inconsistent and limited (Hornberger et al., 2015).

Regulatory and guideline positions caution against standalone use: the FDA stated in 2017 that there are no valid scientific data showing a nipple aspirate test used alone is an effective screening tool for detecting breast cancer, and professional guidelines (NCCN, ACR) state that ductal lavage and cytologic examination of nipple discharge are not recommended for routine screening or diagnostic use.

Provider Actions

Documentation Required

Benefit determination required

Application of coverage criteria depends on the individual's benefit coverage at the time of request; verify Medicare and Medicaid specifications per Section VII and applicable government policies.

Application of coverage criteria is dependent upon the individual's benefit coverage at the time of the request; verify Medicare/Medicaid specifications per Section VII and applicable government policies.

Background & Definitions

Nipple aspiration and ductal lavage are noninvasive techniques developed to collect breast epithelial cells for cytologic examination, primarily to evaluate nipple discharge and explore potential biomarkers for breast cancer risk. Ductal lavage was introduced to improve cellular yield from nipple aspirate fluid given often scant cellularity from simple expression.

Regulatory and guideline context: the FDA (2017) warned that nipple aspirate tests are not effective substitutes for mammography when used alone, and major guideline bodies (NCCN, ACR) do not recommend routine use of ductal lavage or cytologic examination of nipple discharge for breast cancer screening or diagnosis.

Term	Definition
NAF
Nipple aspirate fluid
Ductal lavage
Technique developed to enhance collection of breast epithelial cells via lavage of ducts
PED
Proliferative epithelial disease

Evidence Summary

Overall strength and direction of evidence: studies show low sensitivity and variable specificity for cytology of nipple-derived specimens, with limited and inconsistent prospective data suggesting a modest association with future cancer risk (approximately 2.1-fold in some analyses).

Evidence	Key finding
Sensitivity/Specificity (Kooistra et al., 2009)
sensitivity 17%, specificity 66%
Meta-analysis (Hornberger et al., 2015)
abnormal cytology associated with 2.1-fold higher risk in prospective studies
FDA statement (2017)
No valid scientific data that nipple aspirate test alone is effective for detection of breast cancer
NCCN/ACR positions
Do not recommend routine use of ductal lavage or cytologic examination of nipple discharge for screening/diagnosis

Revision History

clarified (material)Latest

Policy states that cytologic analysis of epithelial cells from nipple aspirations (including ductal lavage and suction techniques) to assess breast cancer risk and manage patients at high risk of breast cancer DOES NOT MEET COVERAGE CRITERIA. (Reflects conclusion based on cited evidence and guideline statements from NCCN, ACR, FDA, ASBS and systematic reviews; sensitivity 17%, specificity 66%; abnormal cytology associated with 2.1-fold higher risk in prospective studies.)

OpenPayer